Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Short-term Investments: 2009-2024

Historic Short-term Investments for Gyre Therapeutics (GYRE) over the last 13 years, with Dec 2024 value amounting to $14.9 million.

  • Gyre Therapeutics' Short-term Investments rose 112.95% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year increase of 112.95%. This contributed to the annual value of $14.9 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Gyre Therapeutics reported Short-term Investments of $14.9 million as of FY2024, which was up 495.05% from $2.5 million recorded in FY2021.
  • Over the past 5 years, Gyre Therapeutics' Short-term Investments peaked at $49.0 million during FY2020, and registered a low of $2.5 million during FY2021.
  • In the last 1 years, Gyre Therapeutics' Short-term Investments had a median value of $14.9 million in 2024 and averaged $14.9 million.
  • Data for Gyre Therapeutics' Short-term Investments shows a maximum YoY plummeted of 94.89% (in 2021) over the last 5 years.
  • Gyre Therapeutics' Short-term Investments (Yearly) stood at $49.0 million in 2020, then slumped by 94.89% to $2.5 million in 2021, then reached $14.9 million in 2024.